Additional Grant of Patent Rights Version 2

"Software" means the crdt-merge software distributed by Ryan Gillespie /
Optitransfer.

Ryan Gillespie / Optitransfer hereby grants to each recipient of the
Software ("you") a perpetual, worldwide, royalty-free, non-exclusive,
irrevocable (subject to the termination provision below) license under
any Necessary Claims, to make, have made, use, sell, offer to sell,
import, and otherwise transfer the Software. For avoidance of doubt, no
license is granted under Ryan Gillespie's / Optitransfer's rights in any
patent claims that are infringed by (i) modifications to the Software
made by you or any third party or (ii) the Software in combination with
any software or other technology.

The license granted hereunder will terminate, automatically and without
notice, if you (or any of your subsidiaries, corporate affiliates, or
agents) initiate directly or indirectly, or take a direct financial
interest in, any Patent Assertion: (i) against Ryan Gillespie /
Optitransfer or any of its subsidiaries or corporate affiliates,
(ii) against any party if such Patent Assertion arises in whole or in
part from any software, technology, product, or service of Ryan Gillespie
/ Optitransfer or any of its subsidiaries or corporate affiliates, or
(iii) against any party relating to the Software. Notwithstanding the
foregoing, if Ryan Gillespie / Optitransfer or any of its subsidiaries
or corporate affiliates files a lawsuit alleging patent infringement
against you in the first instance, and you respond by filing a patent
infringement counterclaim in that lawsuit against that party that is
unrelated to the Software, the license granted hereunder will not
terminate under section (i) of this paragraph due to such counterclaim.

A "Necessary Claim" is a claim of a patent owned by Ryan Gillespie /
Optitransfer that is necessarily infringed by the Software standing alone.

A "Patent Assertion" is any lawsuit or other action alleging direct,
indirect, or contributory infringement or inducement to infringe any
patent, including a cross-claim or counterclaim.
